Combined sulforaphane and β-sitosterol mitigate olanzapine-induced metabolic disorders in rats: Insights on FOXO, PI3K/AKT, JAK/STAT3, and MAPK signaling pathways
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112904 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Ehab A M El-Shoura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 71524, Egypt. Electronic address: ehabel-shoura@azha…. Hauptthemen laut MEDLINE: Isothiocyanates, Liver, Olanzapine, Signal Transduction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 162 Literaturangaben.
Abstract (Originalsprache)
One of the best antipsychotics for treating schizophrenia and bipolar disorders is olanzapine (OLA). However, its use is restricted owing to unfavorable adverse effects as liver damage, dyslipidemia, and weight gain. The primary objective of the present investigation was to examine the signaling mechanisms that underlie the metabolic disruption generated by OLA. Besides, the potential protective effect of sulforaphane (SFN) and β-sitosterol (βSS) against obesity and metabolic toxicity induced by OLA were inspected as well. A total of five groups of male Wistar rats were established, including the control, OLA, SFN+OLA, βSS+OLA, and the combination + OLA groups. Hepatic histopathology, biochemical analyses, ultimate body weights, liver function, oxidative stress, and pro-inflammatory cytokines were evaluated. In addition to the relative expression of FOXO, the signaling pathways for PI3K/AKT, JAK/STAT3, and MAPK were assessed as well. All biochemical and hepatic histopathological abnormalities caused by OLA were alleviated by SFN and/or βSS. A substantial decrease in systolic blood pressure (SBP), proinflammatory cytokines, serum lipid profile parameters, hepatic MDA, TBIL, AST, and ALT were reduced through SFN or/and βSS. To sum up, the detrimental effects of OLA are mediated by alterations in the Akt/FOXO3a/ATG12, Ras/SOS2/Raf-1/MEK/ERK1/2, and Smad3,4/TGF-β signaling pathways. The administration of SFN and/or βSS has the potential to mitigate the metabolic deficit, biochemical imbalances, hepatic histological abnormalities, and the overall unfavorable consequences induced by OLA by modulating the abovementioned signaling pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 71524, Egypt. Electronic address: ehabel-shoura@azhar.edu.eg.
- Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.
- Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Egypt.
- Department of Pharmacology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
- Department of Medical Physiology, Faculty of Medicine, Menoufia University, Shebeen ElKom, 32511, Egypt.
Zitieren
APA
El-Shoura, E. A. M., Abdelzaher, L. A., Mahmoud, N. I., Farghaly, O. A., Sabry, M., Girgis Shahataa, M., Salem, E. A., Saad, H. M., Elhussieny, O., Kozman, M. R., & Atwa, A. M. (2024). Combined sulforaphane and β-sitosterol mitigate olanzapine-induced metabolic disorders in rats: Insights on FOXO, PI3K/AKT, JAK/STAT3, and MAPK signaling pathways. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112904
Vancouver
El-Shoura EAM, Abdelzaher LA, Mahmoud NI, Farghaly OA, Sabry M, Girgis Shahataa M, et al. Combined sulforaphane and β-sitosterol mitigate olanzapine-induced metabolic disorders in rats: Insights on FOXO, PI3K/AKT, JAK/STAT3, and MAPK signaling pathways. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112904
BibTeX
@article{ElShoura2024,
author = {El-Shoura, Ehab A M and Abdelzaher, Lobna A and Mahmoud, Nesreen I and Farghaly, Omar A and Sabry, Mostafa and Girgis Shahataa, Mary and Salem, Esraa A and Saad, Hebatallah M and Elhussieny, Omnya and Kozman, Magy R and Atwa, Ahmed M},
title = {Combined sulforaphane and β-sitosterol mitigate olanzapine-induced metabolic disorders in rats: Insights on FOXO, PI3K/AKT, JAK/STAT3, and MAPK signaling pathways},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112904}
}
EUVIMED